James Parker, MD
Cardiovascular Disease · Hammond, LANPI 1407888555
Payments from drug & device makers
Across 169 payments — averaging $31.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Medtronic$1K
- Abiomed$724
- Merck$220
- Philips North America LLC$160
- Novartis$145
- plus $1K from 21 others
What the payments were for
- Travel & lodging$1,26824%
- Food & beverage$3,98976%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 28 | $1,725 |
| Medtronic(2 entities) | 36 | $1,016 |
| Abiomed | 24 | $724 |
| Merck | 12 | $220 |
| Philips North America LLC | 4 | $160 |
| Novartis | 8 | $145 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $132 |
| Boston Scientific | 6 | $128 |
| Angiodynamics, Inc. | 1 | $120 |
| E.r. Squibb & Sons, L.L.C. | 6 | $114 |
| Boehringer Ingelheim | 7 | $111 |
| Davol Inc. | 1 | $82 |
| Kestra Medical Technology Services, Inc. | 3 | $73 |
| Novo Nordisk | 3 | $71 |
| GE HealthCare | 2 | $69 |
| Pfizer | 3 | $48 |
| Biosense Webster, Inc. | 2 | $46 |
| AstraZeneca | 3 | $43 |
| Actelion Pharmaceuticals US, Inc. | 1 | $34 |
| Amgen | 2 | $33 |
| Terumo Medical Corporation | 2 | $32 |
| Innovation Technologies Inc | 1 | $31 |
| Acist Medical Systems, Inc. | 1 | $26 |
| Chiesi USA, Inc. | 1 | $20 |
| Johnson & Johnson | 1 | $19 |
| Lexicon Pharmaceuticals, Inc. | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AVEIR$1,259
- Auryon Laser System 100-120 Vac$120
- AURORA EV-ICD MRI SURESCAN$115
- Impella$109
- HawkOne$101
How this compares
$5,257 in reported general payments places this provider in the 60th percentile of 281 cardiovascular disease providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 950 | $782,498 |
| EliquisApixaban | 867 | $711,684 |
| XareltoRivaroxaban | 268 | $209,698 |
| JardianceEmpagliflozin | 236 | $158,617 |
| FarxigaDapagliflozin Propanediol | 170 | $124,899 |
| Bosentan | 12 | $32,335 |
| Repatha SureclickEvolocumab | 50 | $29,831 |
| OzempicSemaglutide | 26 | $24,802 |
| BrilintaTicagrelor | 24 | $14,826 |
| CorlanorIvabradine Hcl | 16 | $10,120 |
| Ranolazine ErRanolazine | 190 | $9,449 |
| Metoprolol Succinate | 875 | $8,869 |
| Flecainide Acetate | 188 | $5,964 |
| VascepaIcosapent Ethyl | 12 | $5,719 |
| DapagliflozinDapagliflozin Propanediol | 11 | $5,137 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $145 | $782,498950 claims |
| PfizerEliquis | $48 | $711,684867 claims |
| Johnson & JohnsonXarelto | $19 | $209,698268 claims |
| Boehringer IngelheimJardiance | $111 | $158,617236 claims |
| AstraZenecaFarxiga, Brilinta | $43 | $139,725194 claims |
| Actelion Pharmaceuticals US, Inc.Bosentan | $34 | $32,33512 claims |
| Novo NordiskOzempic | $71 | $24,80226 claims |
| AmgenCorlanor | $33 | $10,12016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 281 cardiovascular disease providers in Louisiana.
Other cardiovascular disease in Hammond
- Ghiath MikdadiHammond$5.7M
- Georges KhoueiryHammond$16K
- Marc BernsteinSlidell$2.1M
- Anil ChhabraShreveport$1.9M
- Dale PresserCovington$1.7M
- William EavesShreveport$1.6M
- Assad MouhaffelWest Monroe$1.4M
- Wenwu ZhangShreveport$1.1M
- William SmithRuston$694K
- Imran ChaudryMonroe$371K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.